Related by context. All words. (Click for frequent words.) 65 endpoints 61 Surgical Procedures 60 Pooled Analysis 60 Pediatric Patients 60 Demonstrates Significant 60 Combo Therapy 60 Long Term Efficacy 60 Carotid Endarterectomy 60 Unfractionated Heparin 60 Improves Outcomes 60 Heart Failure Patients 60 Regimens 60 Non Inferiority 60 Antiviral Activity 60 Comorbidities 59 Randomized Trials 59 Left Ventricular 59 Statistically Significant 59 Adjuvant Chemotherapy 59 Secondary endpoints 59 Renal Function 59 Diagnostic Tools 59 Hypertensive Patients 59 Demonstrates Efficacy 59 HCV Genotype 59 Patients Receiving 59 Shows Efficacy 59 Breast Cancer Recurrence 59 ACE Inhibitors 59 Antitumor 59 Antitumor Activity 59 Antiplatelet Therapy 59 Inhaled Corticosteroids 58 Prolongs Survival 58 Septic Shock 58 Primary Endpoint 58 Platelet Inhibition 58 Sustained Virologic Response 58 Survival Benefit 58 Clinical Outcome 58 Kidney Function 58 Colorectal Cancer Patients 58 Improves Survival 58 Rheumatoid Arthritis Patients 58 Monotherapy 58 Key Attributes 58 Meta Analysis 58 Platelet Function 58 Clinical Trial Evaluating 58 Immunosuppression 58 Patients Treated With 58 Thrombolysis 58 Significantly Reduces 58 Stable Angina 58 Lipid Lowering 58 LDL Cholesterol 58 Tiotropium 58 Breast Density 58 Patients Undergoing 58 Elderly Patients 58 Protease Inhibitors 57 endpoint 57 Patient Outcomes 57 Lesion 57 Combination Treatment 57 Dose Escalation 57 Genotypes 57 Bare Metal Stents 57 Hormone Refractory Prostate Cancer 57 Reduced Risk 57 Prospective Randomized 57 Viral Load 57 secondary efficacy endpoints 57 Tumor Response 57 Cholesterol Lowering Drug 57 Phase 2b Study 57 Postmenopausal Women 57 Renal Artery 57 Severe Asthma 57 Hospitalized Patients 57 HER2 Positive Breast Cancer 57 Renal Cell Carcinoma 57 Carotid Artery Stenting 57 Randomized Study 57 secondary endpoints 57 Contrast Agents 57 Phase III Trial 57 Brain Metastases 57 Cardiovascular Outcomes 57 Anticancer Activity 57 Well Tolerated 57 Breast Tumors 57 Tolerability 57 Carotid Stenting 57 Drug Eluting 57 ST Segment Elevation 57 Advanced Melanoma 57 Metastatic Colorectal Cancer 57 ENDEAVOR II 57 Vertebral Fracture 57 RECIST Response Evaluation Criteria 57 Treatment Regimen 57 Fracture Risk 56 Cardiac Resynchronization 56 Demonstrates Sustained 56 Stent Restenosis 56 Solid Tumors 56 Overactive Bladder 56 Beta Blockers 56 Therapy Reduces 56 Secondary efficacy endpoints 56 Oral Fingolimod 56 C Reactive Protein 56 JAK Inhibitor 56 Efficacious 56 Pharmacokinetic 56 Chemotherapeutic Agents 56 Cardiotoxicity 56 Diabetic Patients 56 Adjuvant Therapy 56 Pelvic Organ Prolapse 56 Novel Compound 56 Hernia Repair 56 Unstable Angina 56 Patients Treated 56 Investigational Agent 56 ASTEROID 56 Phase IIb Trial 56 Transdermal Patch 56 Lipid Levels 56 Response Evaluation Criteria 56 PRoFESS 56 Events MACE 56 FDA Approvals 56 Improves Quality 56 Randomized Clinical Trial 56 Cardiac Function 56 Intervention Trial 56 BENICAR HCT 56 Controlled Trial 56 Posaconazole 56 Bronchodilator 56 Lupus Drug 56 Observational Study 56 Blood Pressure Drug 56 Naive Patients 56 Investigational Drug 56 Single Dose 56 Functional Outcomes 56 Study Evaluating 56 Combination Therapy 56 Study Demonstrates 56 Epoetin Alfa 56 Primary endpoints 56 Is Well Tolerated 56 Meets Primary Endpoint 56 Phase III Trials 56 prespecified secondary 56 Antiepileptic Drug 56 Patency 56 Cardiovascular Events 55 Pivotal Trials 55 Less Invasive 55 Beta Blocker 55 Acute Myocardial Infarction 55 Immunogenicity 55 Breast Tissue 55 Treated Patients 55 Genes Linked 55 Efficacy 55 ONTARGET 55 Significantly Improved 55 Relapsing Remitting Multiple Sclerosis 55 Subgroup Analysis 55 Prophylactic Treatment 55 Improve Survival 55 Fondaparinux 55 Systolic Blood Pressure 55 Lenalidomide 55 See CLINICAL PHARMACOLOGY 55 Acute Ischemic Stroke 55 Acute Coronary Syndromes 55 Suboptimal 55 Appears Safe 55 Blood Glucose 55 serum phosphorous 55 Stem Cell Transplants 55 Initiate Clinical Trial 55 Knee Osteoarthritis 55 Clinical Efficacy 55 Pioglitazone 55 Randomized Double Blind 55 Randomized Evaluation 55 Could Predict 55 Fewer Side Effects 55 Tablet Formulation 55 ORENCIA ® 55 Risk Stratification 55 Antihypertensive 55 Metastatic Renal Cell Carcinoma 55 Improved Survival 55 SVR# 55 Shows Statistically Significant 55 Postmarketing 55 Infarct 55 Placebo Controlled Trial 55 ACCORD Lipid 55 Bevacizumab 55 Percutaneous Coronary Intervention 55 Uric Acid 55 Protease Inhibitor 55 Targeted Therapy 55 Low Dose 55 Subtypes 55 Efficacy endpoints 55 Bivalirudin 55 Predict Risk 55 Genes Associated 55 Initiated Phase 55 Percutaneous Tibial Nerve Stimulation 55 Nesiritide 55 Significantly Improves 55 Ischemic Stroke 55 Long Term Outcomes 55 Hypercholesterolemia 55 Immune Cell 55 Controlled Study 55 Treatment Naive HIV 55 Minimally Invasive Treatment 55 Venous Thromboembolism 54 Treatment Naive 54 PRECISE 54 Pharmacokinetics PK 54 Prognostic Value 54 Main Outcome Measure 54 Non Responders 54 Atherosclerotic 54 Adjunctive Therapy 54 WARNINGS Myopathy Rhabdomyolysis 54 Nilotinib 54 Pegylated Liposomal Doxorubicin 54 Clinical Trial Results 54 Clinical Outcomes 54 Clinical Evaluation 54 Randomised 54 Multiple Myeloma Patients 54 concomitant medications 54 Tigecycline 54 Pivotal Phase 54 CONTRAINDICATIONS 54 Diagnostic Accuracy 54 Glatiramer Acetate 54 Aromatase Inhibitors 54 Epilepsy Drug 54 Left Atrial 54 TAXUS ATLAS 54 Cholinesterase Inhibitors 54 Rheumatoid Arthritis Drug 54 Catheter Ablation 54 Hormone Receptor Positive 54 multicenter multinational 54 Dual Antiplatelet Therapy 54 Clinical Remission 54 Demonstrated Significant 54 Contrast Agent 54 Phase III Clinical Trial 54 Sustained Efficacy 54 dose atorvastatin 54 Pivotal Trial 54 Ranolazine 54 Pharmacokinetic Study 54 Drug Eluting Stents 54 Relapsing Multiple Sclerosis 54 Previously Treated 54 exploratory endpoints 54 EURIDIS 54 Anti Tumor Activity 54 Adjuvant Treatment 54 Testing Methodology 54 Showed Significant 54 Estrogen Receptor 54 Radiation Dose 54 FDA Okays 54 Gene Mutation 54 Unmet Medical 54 Left Ventricular Dysfunction 54 Pivotal Study 54 Study Shows Significant 54 Anticoagulant 54 Valopicitabine NM# 54 Randomized Controlled 54 Virologic 54 Highly Accurate 54 Phase 2b Clinical Trial 54 Lung Cancer Trial 54 Newly Diagnosed Multiple Myeloma 54 NICE Recommends 54 Immunogenic 54 Randomized Clinical Trials 54 Diabetic Foot Ulcer 54 Significantly Reduced 54 pharmacodynamic parameters 54 Patient Populations 54 Myocardial Ischemia 54 Achieves Primary Endpoint 54 APTIVUS 54 Major Adverse Cardiac 54 Proves Effective 54 Secondary endpoints included 54 Myocardial Infarction Study 54 Treatment Naive Patients 54 Interferon Gamma 54 Recurrent Breast Cancer 54 Ischemic 54 Significant Improvements 54 secondary endpoint 54 HCV Protease Inhibitor 54 Phase 2a Trial 54 oral FTY# 54 daily Infergen 54 Intracranial Aneurysms 54 Brain Scans 54 Osteoporosis Treatment 54 Neoadjuvant Chemotherapy 54 Secondary Endpoints 54 Restenosis 54 Prospective Multicenter 54 Oropharyngeal 54 Sirolimus Eluting 54 Valsartan 54 Autologous Stem Cell Transplantation 54 Orthostatic Hypotension 54 Prognostic Significance 54 ARIXTRA 54 Sirolimus Eluting Stent 54 Symptom Relief 54 Dose Response 54 Desvenlafaxine Succinate 54 Angiographic 54 SABCS 54 Polymerase Inhibitor 54 Novel Oral 54 STRIDE PD 54 Novel Inhibitor 54 subanalysis 54 Endarterectomy 53 #mg BID [003] 53 Kidney Transplants 53 Test Methodology 53 Performance Benchmarks 53 Epirubicin 53 Zoledronic Acid 53 Depressive Symptoms 53 Fecal Incontinence 53 Peginterferon 53 XIENCE V PROMUS Stent 53 pain palliation 53 Hepatitis C Patients 53 Free Survival PFS 53 Progenitor Cells 53 Cyclooxygenase 2 53 Clinical Validation 53 alfuzosin 53 Efficacy Trial 53 Anticoagulation 53 Radical Prostatectomy 53 Asthma Treatment 53 Lung Cancer Risk 53 Innate Immune 53 Orally Active 53 Patients Suffering 53 hematological parameters 53 Pain Intensity 53 Abciximab 53 Localized Prostate Cancer 53 Stomach Ulcer 53 Pharmacokinetic PK 53 Vildagliptin 53 Statistical Significance 53 Viral Suppression 53 Study Reinforces 53 Stent Thrombosis 53 Kidney Transplant Patients 53 Demonstrates Statistically Significant 53 Malware Detection 53 Echocardiographic 53 Pivotal Phase III 53 prospectively defined 53 Sipuleucel T 53 CAMMS# 53 ILLUSTRATE 53 Data Suggest 53 Neoadjuvant 53 Severe Sepsis 53 Investigational Treatment 53 Platinol ® 53 Diagnostic Tests 53 Watchful Waiting 53 Antiviral Therapy 53 TM Drug Eluting 53 Demonstrates Positive 53 Diuretic 53 Gene Expression Analysis 53 Advanced Colorectal Cancer 53 Loading Dose 53 nonrandomized 53 Phase III Pivotal Trial 53 Treating Chronic 53 Benign Prostatic Hyperplasia 53 Drug Candidate 53 Diabetic Neuropathy 53 Disease Progression 53 Wound Closure 53 Fungal Infections 53 Treatment Outcome 53 Aliskiren 53 Clopidogrel 53 Blood Pressure Lowering 53 Advanced Prostate Cancer 53 PRECAUTIONS Drug Interactions 53 Stenting 53 Combination REOLYSIN R 53 sirolimus eluting stents 53 Carotid 53 TRANSFORMS 53 Coronary CTA 53 Xelox 53 Subsets 53 FDA Clears 53 unfractionated heparin UFH 53 Moxifloxacin 53 Randomized Controlled Trials 53 Balloon Angioplasty 53 Capecitabine 53 Chronic Hepatitis B 53 Infliximab 53 Compliance Requirements 53 Interferon Beta 53 Chronic Hepatitis C 53 Chemoradiation 53 Shows Promising 53 Potent Inhibitor 53 Helps Predict 53 EVEREST II 53 Preclinical Data 53 Deep Venous Thrombosis 53 Insulin Glargine 53 Hypertrophy 53 Phase IIIb 53 Lower Limb 53 Proven Effective 53 Multicenter Randomized 53 Clinical Trial Data 53 relapsed MM 53 Blood Pressure Drugs 53 Peginterferon Alfa 2a 53 RE LY ® 53 Infected Patients 53 patients evaluable 53 Preclinical Study 53 Drug Regimen 53 Randomized controlled 53 Refractory Hodgkin Lymphoma 53 Enzyme Linked 53 Evaluation Criteria 53 Laryngeal Cancer 53 Study Showed 53 Pulmonary Arterial Hypertension 52 Study Shows Benefits 52 Cognitive Impairment 52 efficacy endpoints 52 demonstrated clinically meaningful 52 Elitek 52 Eluting 52 Oral Mucositis 52 virologic responses 52 prospectively stratified 52 ACTEMRA TM 52 Relapsed Refractory 52 Lung Tumors 52 Antipsychotic 52 NDA Submission 52 Omalizumab 52 Prognostic 52 BENICAR 52 Trial Evaluating 52 Coronary Artery Bypass Surgery 52 Signaling Pathways 52 Complicated Skin 52 Adverse Event 52 Pharmacodynamics 52 Phase IIb Clinical Trial 52 Atopic Dermatitis 52 CYPHER R Sirolimus Eluting 52 Profile SEP 52 Adalimumab 52 tolerability pharmacokinetics 52 Histologic 52 Glycemic Control 52 Exacerbations 52 DASISION 52 Anti TNF 52 morphometric vertebral fractures 52 INC# 52 Treatment Resistant 52 treatment naive genotype 52 BENCHMRK 52 Quantifiable 52 Radiofrequency Ablation 52 Non Invasive 52 HORIZONS AMI 52 HDL Cholesterol 52 primary endpoints 52 Eluting Coronary Stent System 52 melphalan prednisone 52 Fluorouracil 52 trials RCTs 52 Bioavailability 52 Radiofrequency Ablation RFA 52 Contraindications 52 Mycophenolate Mofetil 52 Genetic Markers 52 Randomized Double blind 52 Intraocular Pressure 52 Menstrual Pain 52 Radiation Exposure 52 Ankle Brachial Index 52 REMINYL ® 52 Anti Tumor 52 Oral Glucose Tolerance 52 Androgen Deprivation Therapy 52 Stent Placement 52 Demonstrate Significant 52 Gout Drug 52 Investigational Compound 52 Phase 2a Clinical Trial 52 Diabetic Foot Ulcers 52 Generalized Anxiety Disorder 52 Hemodialysis Patients 52 Endovascular Treatment 52 TO AVOID PREGNANCY WHILE 52 Prostate Cancer Risk 52 VerifyNow 52 MYCAMINE 52 Heart Failure Therapy 52 fosbretabulin 52 Immune Responses 52 Psoriasis Drug 52 Multicenter 52 Atypical Antipsychotics 52 mycophenolate mofetil 52 Treatment Regimens 52 CRp 52 Late Breaker 52 Natalizumab 52 Phase Ib Clinical Trial 52 Rasilez Tekturna 52 Metastatic Melanoma 52 Colorectal Cancers 52 Follicular Lymphoma 52 IND Application 52 First Patient Dosed 52 prespecified 52 Paclitaxel Eluting 52 YERVOY 52 Suicidality 52 INFERGEN 52 certolizumab 52 Guideline Update 52 Randomized Controlled Trial 52 Bosutinib 52 Toxicities 52 Active Ulcerative Colitis 52 Effective Treatments 52 Pemetrexed 52 RAPAFLO R 52 dosing cohorts 52 TAXUS Liberte Long 52 Endeavor Drug Eluting 52 baseline LDH 52 Capsules CII 52 Betaferon R 52 Crohn Disease Activity 52 Proteinuria 52 CIMZIA TM certolizumab pegol 52 Colorectal Cancer Risk 52 candesartan cilexetil 52 DAS# CRP 52 Spectrum Pharmaceuticals Announces 52 Solution Accelerates 52 Main Outcome Measures 52 Scale PANSS 52 Telithromycin 52 BOLDER II 52 Postoperative Ileus 52 Pegylated Interferon 52 CARE HF 52 Randomized Phase 52 Chronic Heart Failure 52 Tyrosine Kinase Inhibitor 52 Phase 2b Trial 52 Randomized Phase II 51 Clinical Guideline 51 Efficacy Study 51 Inhalation Solution 51 GOUT 51 Microalbuminuria 51 ACCOMPLISH 51 Adverse Effects 51 Receives Orphan Drug Designation 51 Boceprevir 51 APPRAISE 51 Pertuzumab 51 Invasive Fungal Infections 51 RoACTEMRA 51 Systematic Approach 51 colesevelam HCl 51 specific antigen PSA 51 antiepileptics 51 mucosal healing 51 Eculizumab 51 Varies Widely 51 Prospective Randomized Trial 51 Hepatitis C Genotype 51 Psoriasis Area 51 alteplase 51 alicaforsen enema 51 Schizophrenia Treatment 51 Pharmacogenetic 51 Bosentan 51 Outpatient Setting 51 PET Scanner 51 Adefovir 51 Peripheral Arterial 51 Tumor Growth 51 Kidney Donors 51 Statin Therapy 51 lacosamide 51 Decitabine 51 Peginterferon Alfa 2b 51 Carotid Revascularization Endarterectomy vs. 51 Natural Catastrophe Stress 51 nausea photophobia 51 multicenter randomized controlled 51 HCV SPRINT 51 Fatty Liver 51 Therapeutic Efficacy 51 blood Phe 51 Bone Mineral Density 51 Chemotherapy Improves 51 Low Density Lipoprotein Cholesterol 51 EXPAREL ™ 51 Denufosol 51 ATACAND 51 Mortality Risk 51 COPD Exacerbations 51 Intravascular 51 Adenomas 51 Index CDAI 51 chills fever headache 51 efficacy tolerability 51 ISTODAX ® 51 Edge STudy 51 RE LY 51 4mg/kg 51 EBMT criteria 51 Novel Mechanism 51 Immunomodulatory 51 Heterogeneity 51 Intravitreal 51 Ozarelix 51 Relapsed Multiple Myeloma 51 Montgomery Asberg Depression 51 Initiates Clinical Trial 51 sirolimus eluting 51 blood Phe levels 51 zonisamide SR 51 #mg BID [001] 51 Phase III Clinical Trials 51 Completes Patient Enrollment 51 tipranavir 51 B Cell Lymphoma 51 Daptomycin 51 CIBIC plus 51 Effectively Treats 51 Diagnostic Criteria 51 Study Analyzes 51 Beta Amyloid 51 mcg QD 51 Golimumab 51 Multicenter Trial 51 Coronary Revascularization 51 Exhaled Nitric Oxide 51 Efficacy Results 51 Magnetic Stimulation 51 Intravesical 51 hepatic enzymes 51 Fixed Dose 51 Sleep Disturbances 51 Prophylaxis 51 NEVO RES 51 lipid lowering agents 51 Double Blind Placebo 51 PEGylated interferon beta 1a 51 RE MODEL 51 PASI scores 51 Trobalt 51 Cardiac Marker 51 Polyp Prevention Trial 51 undetectable HBV DNA 51 pegylated interferon alfa 2b 51 Radiation Doses 51 Dasatinib 51 Hepatotoxicity 51 Breast Carcinoma 51 Secondary endpoints include 51 Corticosteroid 51 FOLPI 51 Solid Tumours 51 TAXUS Stent 51 crizotinib PF # 51 FOLFOX6 51 Cardiovascular Disease Risk 51 Panic Disorder 51 GLIADEL R Wafer 51 Genetic Variants 51 Genetic Variations 51 haematologic 51 Hsp# Inhibitor 51 PREZISTA r arm 51 Plus Ribavirin 51 Generalised Anxiety Disorder 51 p# antigen 51 ritonavir boosted 51 serum triglycerides 51 Induces 51 pharmacokinetics PK 51 Significant Reduction 51 Biphasic 51 Cinacalcet 51 Aortic Stenosis 51 randomized Phase IIb 51 ADCS CGIC 51 Solid Tumors RECIST 51 Fludarabine 51 Bare Metal Stent 51 Endothelial Function 51 D Dimer 51 pharmacodynamic PD 51 Oral Insulin 51 Coronary Intervention 51 Quetiapine 51 Drug Eluting Stent 51 Trandolapril 51 Successful Implementation 51 Scintigraphy 51 Hyperlipidemia 51 teriflunomide 51 Gene Variant 51 multicenter prospective 51 pharmacokinetic PK profile 51 oral rivaroxaban 51 Oral Anticoagulant 51 Xeloda ® 51 Symptom Severity 51 YMRS 51 Metastatic Prostate Cancer 51 Completes Enrollment 51 Anti Inflammatory Drugs 51 Kidney Transplant Recipients 51 nausea somnolence 51 Pressure Monitoring 51 atazanavir ritonavir 50 randomized multicenter trial 50 Allogeneic 50 BARACLUDE ® 50 Glufosfamide 50 CIMZIA R 50 active comparator 50 Fulvestrant 50 efavirenz EFV 50 Score IPSS 50 ARIXTRA R 50 ascending dose 50 Castration Resistant Prostate Cancer 50 Versus Placebo 50 WARFARIN 50 Flexible Deployment 50 baseline HbA1c 50 TMC# r 50 boosted protease inhibitor 50 evaluable 50 Etanercept 50 Interferon Alpha 50 PHASE III 50 Tolvaptan 50 Inflammatory Response 50 Nebulized 50 Complete Remission 50 Detect Cancer 50 F FDG PET 50 Pulmonary Artery 50 Cost Effectiveness 50 IIIa inhibitor 50 Diabetic Nephropathy 50 dose regimens 50 Double Blind Randomized 50 Hematocrit 50 Universal Flu Vaccine 50 icatibant 50 DAPT 50 catheter occlusion 50 surrogate endpoint 50 Reduces Pain 50 dosage regimens 50 Medoxomil 50 CHARM Added 50 Score TOS 50 Oral Fluid 50 Preclinical Efficacy 50 Co Receptor Tropism 50 HDAC Inhibitor 50 Coronary Artery Calcium 50 mg BID 50 Hematologic 50 pharmacodynamic effects 50 Quadrivalent 50 Vitro Activity 50 composite endpoint 50 Cimzia TM 50 phase IIIb 50 Long Lesion 50 tipranavir r 50 Mammographic 50 Betaferon ® 50 Demonstrates Superior 50 rosuvastatin #mg 50 Molecular Weight Heparin 50 Lubiprostone 50 ABC/3TC 50 Myocardial 50 Urinary Catheter 50 Negative Symptoms 50 CLINICAL PHARMACOLOGY 50 EGFR HER2 50 infliximab Remicade 50 Eluting Stent 50 Pharmacodynamic 50 transcranial Doppler ultrasound 50 Neonates 50 Evaluable 50 prospective randomized controlled 50 Present Preclinical Data 50 Fidaxomicin 50 Cognitive Abilities 50 Cognitive Function 50 Apolipoprotein B 50 Low Incidence 50 TRITON TIMI 50 FASLODEX 50 Metabolites 50 primary efficacy endpoints 50 Predict Breast Cancer 50 Beneficial Effects 50 Disease Activity 50 CAVEATS 50 Cypher Sirolimus 50 secondary efficacy endpoint 50 Cardiogenic Shock 50 DCE MRI 50 Mg Uk 50 APTIVUS r 50 Ambulatory Blood Pressure 50 HAM D# 50 Amplicor 50 Dosages 50 Visceral Fat 50 Usability Enhancements 50 Skeletal Muscle 50 Analytical Method 50 CIMZIA ™ 50 Renal Insufficiency 50 Enoxaparin 50 Previously Untreated 50 IN PATIENTS WITH 50 Dyslipidemia 50 Parathyroid Hormone 50 relapsing multiple sclerosis 50 Stent Implantation 50 Darunavir 50 PERSEUS 50 Brain Atrophy 50 Induction Chemotherapy 50 Sustained Release 50 Genetic Marker 50 Vidaza azacitidine 50 INVEGA ® 50 interobserver 50 Hepatitis C Treatment 50 Improves Accuracy 50 Pathologic 50 Reduced Incidence 50 β blockers 50 Virtual Colonoscopy 50 Myocardial Infarction TIMI 50 Sexual Satisfaction 50 Brief Psychiatric 50 Correlates 50 Partial Seizures 50 Desvenlafaxine 50 Placebo Controlled Study 50 Competitive Differentiator 50 symptomatic VTE 50 -0 - 50 HIV RNA 50 Hormonal Therapy 50 rFVIIa 50 Risedronate 50 aripiprazole Abilify 50 BARACLUDE R 50 Strongly Linked 50 Alkaline Phosphatase 50 BAL# [002] 50 Expanded Disability Status 50 COPAXONE R 50 FOLFIRI 50 Folfox 50 #:# randomization 50 nicardipine 50 bronchial hyperresponsiveness 50 Topical Gel 50 SF #v# 50 Melphalan 50 Clostridium difficile Infection 50 intratympanic 50 TLUS 50 Reveals Significant 50 Scale EDSS score 50 Candesartan 50 Multicenter Randomized Double 50 Demonstrates Potent 50 Adjunctive 50 Confirms Efficacy 50 Hepatic Encephalopathy 50 Severity MSCS score 50 Disease Severity 50 cinacalcet 50 Lung Function 50 QT Prolongation 50 erlotinib Tarceva ® 50 Differentially 50 Significant Improvement 50 olanzapine LAI 50 Sleep Apnea Treatment 50 Nocturia 49 Fibromyalgia Impact Questionnaire 49 Roche COBAS 49 divalproex sodium 49 Decompensated Heart Failure 49 abacavir lamivudine 49 primary endpoint 49 DEFER 49 Solid Tumors criteria 49 NSABP B 49 Partial Onset Seizures 49 Bayer Onyx 49 Score DAS 49 Colorectal Screening 49 Hepatocellular Carcinoma 49 Kinase Inhibitor 49 sunitinib malate 49 SCH # 49 Gemcitabine 49 Endovascular Valve Edge 49 Cervista HPV 49 Liver Function 49 aspartate aminotransferase AST 49 irbesartan 49 Nicotine Addiction 49 Sleep Disturbance 49 PEG IFN 49 Paclitaxel Carboplatin 49 Fecal Occult Blood 49 multicentre randomized 49 SPIRIT III 49 Tipranavir 49 Traficet EN 49 ACC AHA SCAI 49 dual endothelin receptor antagonist 49 Modifiable 49 briakinumab 49 randomized controlled clinical trials 49 glycosylated hemoglobin levels 49 Microplasmin 49 Dapagliflozin 49 Quantitation 49 Neuroprotective Effects 49 eNO 49 Antiretroviral Therapy